Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Profit After Tax data on record, last reported at -$33.0 million in Q4 2025.

  • For Q4 2025, Profit After Tax rose 12.11% year-over-year to -$33.0 million; the TTM value through Dec 2025 reached -$144.7 million, up 52.03%, while the annual FY2025 figure was -$144.7 million, 52.03% up from the prior year.
  • Profit After Tax reached -$33.0 million in Q4 2025 per AMLX's latest filing, up from -$34.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $22.1 million in Q2 2023 and bottomed at -$118.8 million in Q1 2024.
  • Average Profit After Tax over 5 years is -$34.2 million, with a median of -$35.1 million recorded in 2025.
  • Peak YoY movement for Profit After Tax: surged 140.83% in 2023, then crashed 7652.0% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$28.3 million in 2021, then plummeted by 50.66% to -$42.7 million in 2022, then skyrocketed by 111.08% to $4.7 million in 2023, then crashed by 893.62% to -$37.5 million in 2024, then rose by 12.11% to -$33.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$33.0 million in Q4 2025, -$34.4 million in Q3 2025, and -$41.4 million in Q2 2025.